Patents by Inventor Brian W. Metcalf

Brian W. Metcalf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS
    Publication number: 20170050942
    Abstract: The present invention relates to 3-cycloalkylaminopyrrolidine derivatives of the formula I: (wherein R1, R2, R3, R4, R5, R6, R7, X, Y and Z are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as modulators of the CCR2 and/or CCR5 receptor. The compounds and compositions of the invention may bind to chemokine receptors, e.g., the CCR2 and/or CCR5 chemokine receptors, and are useful for treating diseases associated with chemokine, e.g., CCR2 and/or CCR5, activity, such as atherosclerosis, restenosis, lupus, organ transplant rejection and rheumatoid arthritis.
    Type: Application
    Filed: November 4, 2016
    Publication date: February 23, 2017
    Inventors: Chu-Biao Xue, Brian W. Metcalf, Amy Qi Han, Darius J. Robinson, Changsheng Zheng, Anlai Wang, Yingxin Zhang
  • PYRIMIDINONES AS PI3K INHIBITORS
    Publication number: 20170050987
    Abstract: The present invention provides pyrimidinones that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Application
    Filed: July 27, 2016
    Publication date: February 23, 2017
    Inventors: Yun-Long Li, Brian W. Metcalf, Andrew P. Combs
  • AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases
    Publication number: 20170035751
    Abstract: The present invention provides a compound of Formula I or Formula II: enantiomer, diastereomer, prodrug, solvate, metabolite, or pharmaceutically acceptable salt thereof, wherein constituent variables are provided herein. The compounds of Formula I and II are modulators of metalloproteases and are useful in treating diseases associated with metalloprotease activity such as arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions.
    Type: Application
    Filed: July 7, 2016
    Publication date: February 9, 2017
    Inventors: Wenqing Yao, Jincong Zhuo, Meizhong Xu, Fenglei Zhang, Brian W. Metcalf
  • SALTS OF (S)-7-(1-(9H-PURIN-6-YLAMINO)ETHYL)-6-(3-FLUOROPHENYL)-3-METHYL-5H-THIAZOLO[3,2-A]PYRIMIDIN-5-ONE
    Publication number: 20160362424
    Abstract: The present invention relates to salt forms of the phosphoinositide 3-kinase (PI3K) inhibitor (S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one, pharmaceutical compositions comprising the same, and methods of using the salts and compositions for the treatment of PI3K-associated diseases such as cancer.
    Type: Application
    Filed: May 10, 2016
    Publication date: December 15, 2016
    Inventors: Yun-Long Li, Brian W. Metcalf, Hui-Yin Li
  • CRYSTALLINE FORMS OF A PI3K INHIBITOR
    Publication number: 20160362425
    Abstract: The present invention is related to crystalline forms of (S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one which is a PI3K inhibitor useful in the treatment of cancer and other diseases.
    Type: Application
    Filed: May 10, 2016
    Publication date: December 15, 2016
    Inventors: Yun-Long Li, Brian W. Metcalf, Hui-Yin Li
  • COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN
    Publication number: 20160332984
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Application
    Filed: December 28, 2015
    Publication date: November 17, 2016
    Inventors: Brian W. Metcalf, Jason R. Harris, Zhe Li, Stephen L. Gwaltney, II
  • Compounds and uses thereof for the modulation of hemoglobin
    Patent number: 9458139
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: October 4, 2016
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Qing Xu, Zhe Li, Brian W. Metcalf
  • Pyrimidinones as PI3K inhibitors
    Patent number: 9434746
    Abstract: The present invention provides pyrimidinones that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Grant
    Filed: January 2, 2014
    Date of Patent: September 6, 2016
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yun-Long Li, Brian W. Metcalf, Andrew P. Combs
  • Compounds and uses thereof for the modulation of hemoglobin
    Patent number: 9422279
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: August 23, 2016
    Assignee: GLOBAL BLOOD THERAPEUTICS, INC.
    Inventors: Brian W. Metcalf, Zhe Li
  • AZA spiro alkane derivatives as inhibitors of metalloproteases
    Patent number: 9403775
    Abstract: The present invention provides a compound of Formula I or Formula II: enantiomer, diastereomer, prodrug, solvate, metabolite, or pharmaceutically acceptable salt thereof, wherein constituent variables are provided herein. The compounds of Formula I and II are modulators of metalloproteases and are useful in treating diseases associated with metalloprotease activity such as arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: August 2, 2016
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Wenqing Yao, Jincong Zhuo, Meizhong Xu, Fenglei Zhang, Brian W. Metcalf
  • FORMULATIONS COMPRISING WETTING AGENTS AND COMPOUNDS FOR THE MODULATION OF HEMOGLOBIN (S)
    Publication number: 20160206604
    Abstract: This invention provides pharmaceutical formulations for the allosteric modulation of hemoglobin (S) and methods for their use in treating disorders mediated by hemoglobin (S) and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Application
    Filed: August 25, 2014
    Publication date: July 21, 2016
    Inventor: Brian W. METCALF
  • COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN
    Publication number: 20160152602
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Application
    Filed: July 2, 2015
    Publication date: June 2, 2016
    Applicant: GLOBAL BLOOD THERAPEUTICS, INC.
    Inventors: Qing Xu, Zhe Li, Brian W. Metcalf
  • Processes for preparing JAK inhibitors and related intermediate compounds
    Patent number: 9290506
    Abstract: The present invention is related to processes for preparing chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines of Formula III, and related synthetic intermediate compounds. The chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines are useful as inhibitors of the Janus Kinase family of protein tyrosine kinases (JAKs) for treatment of inflammatory diseases, myeloproliferative disorders, and other diseases.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: March 22, 2016
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Jiacheng Zhou, David Meloni, Yongchun Pan, Mei Li, Pingli Liu, Brian W. Metcalf, Tai-Yuen Yue
  • COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN
    Publication number: 20160046613
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Application
    Filed: March 10, 2014
    Publication date: February 18, 2016
    Applicant: GLOBAL BLOOD THERAPEUTICS, INC.
    Inventors: Brian W. METCALF, Zhe LI, Qing XU, Stephen L. GWALTNEY, II, Jason R. HARRIS, Calvin W. YEE
  • COMPOSITIONS AND METHODS FOR THE MODULATION OF HEMOGLOBIN (S)
    Publication number: 20160038474
    Abstract: This invention provides pharmaceutical compositions for the aliosteric modulation of hemoglobin (S) and methods for their use in treating disorders mediated by hemoglobin (S) and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Application
    Filed: March 10, 2014
    Publication date: February 11, 2016
    Applicant: Global Blood Therapeutics, Inc.
    Inventors: Uma SINHA, Brian W. METCALF, Donna OKSENBERG, Kobina N. DUFU, Mira P. PATEL
  • COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN
    Publication number: 20160031904
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Application
    Filed: March 10, 2014
    Publication date: February 4, 2016
    Applicant: GLOBAL BLOOD THERAPEUTICS, INC.
    Inventors: Zhe LI, Qing XU, Brian W. METCALF, Stephen L. GWALTNEY, II, Jason R. HARRIS, Calvin W. YEE
  • COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN
    Publication number: 20160031865
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Application
    Filed: March 10, 2014
    Publication date: February 4, 2016
    Applicant: Global Blood Therapeutics, Inc.
    Inventors: Zhe LI, Qing XU, Brian W. METCALF, Stephen L. GWALTNEY, II, Jason R. HARRIS, Calvin W. YEE
  • 1:1 adducts of sickle hemoglobin
    Patent number: 9248199
    Abstract: Provide herein are 1:1 adducts of sickle hemoglobin (HbS) and a compound of formula (I), as defined herein, suitable as modulators of HbS, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Grant
    Filed: January 29, 2014
    Date of Patent: February 2, 2016
    Assignee: GLOBAL BLOOD THERAPEUTICS, INC.
    Inventor: Brian W. Metcalf
  • COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN
    Publication number: 20160024127
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Application
    Filed: March 10, 2014
    Publication date: January 28, 2016
    Applicant: Global Blood Therapeutics, Inc.
    Inventors: Jason R. HARRIS, Brian W. METCALF, Zhe LI, Stephen L. GWALTNEY, II
  • Amido Compounds And Their Use As Pharmaceuticals
    Publication number: 20150329561
    Abstract: The present invention relates to inhibitors of 11-? hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-? hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
    Type: Application
    Filed: July 24, 2015
    Publication date: November 19, 2015
    Inventors: Wenqing Yao, Jincong Zhuo, Meizhong Xu, Colin Zhang, Brian W. Metcalf, Chunhong He, Ding-Quan Qian